Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant carboplatin + paclitaxel for metastatic vulvar carcinoma
2019-000851-15Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and paclitaxel in vulvar squamous cell carcinoma (VSCC) and cancer, sponsored by Netherlands Cancer Institute. Primary endpoints: response rate of carboplatin and paclitaxel and tumor size reduction. Started Nov 2019; status: active.
02
Drugs
carboplatinpaclitaxel
03
Conditions
vulvar squamous cell carcinoma (VSCC)cancer
Beyond the preview
Go deeper on 2019-000851-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000851-15.